Enzo Biochem, Inc.
ENZ was delisted on the 17th of April, 2025.
54 hedge funds and large institutions have $43.8M invested in Enzo Biochem, Inc. in 2022 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 13 reducing their positions, and 3 closing their positions.
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
6% more funds holding
Funds holding: 51 → 54 (+3)
6% more call options, than puts
Call options by funds: $115K | Put options by funds: $109K
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
29% less capital invested
Capital invested by funds: $62M → $43.8M (-$18.2M)
31% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VCA
VIEX Capital Advisors
Sunny Isles Beach,
Florida
|
+$252K |
| 2 |
V
Veritable
Wilmington,
Delaware
|
+$246K |
| 3 |
PCM
Potomac Capital Management
New York
|
+$155K |
| 4 |
VF
Virtu Financial
New York
|
+$74.5K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$54.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFM
Boothbay Fund Management
New York
|
-$1.57M |
| 2 |
Morgan Stanley
New York
|
-$167K |
| 3 |
AE
AMH Equity
Great Neck,
New York
|
-$87K |
| 4 |
EMG
ETF Managers Group
Summit,
New Jersey
|
-$43K |
| 5 |
State Street
Boston,
Massachusetts
|
-$30.9K |
ENZ Hedge Fund Activity: Q2 2022 in Review
54 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Enzo Biochem, Inc. (ENZ) for Q2 2022, worth a combined $43.8M — down 29% from $62M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new ENZ positions and 3 closed out — a net gain of 3 holders — while 9 added to existing stakes and 13 trimmed.
The largest buyer was VIEX Capital Advisors, adding an estimated $252K. The largest seller was Boothbay Fund Management, exiting entirely with an estimated $1.57M sold.
- 54 institutional investors held Enzo Biochem, Inc. (ENZ) as of Q2 2022, up from 51 in Q1 2022.
- Funds reported $43.8M of Enzo Biochem, Inc. stock for Q2 2022, down 29% quarter-over-quarter.
- 6 funds opened new Enzo Biochem, Inc. positions in Q2 2022 and 3 closed out, a net change of +3 holders.
- The largest Enzo Biochem, Inc. buyer in Q2 2022 was VIEX Capital Advisors, an estimated $252K added.
- The largest Enzo Biochem, Inc. seller in Q2 2022 was Boothbay Fund Management, an estimated $1.57M sold.
Based on aggregated 13F filings for Q2 2022.